Li Jia1, Shihua Luo2,3, Xiang Ren4, Yang Li2, Jialei Hu2, Bing Liu2, Lifen Zhao2, Yujia Shan2, Huimin Zhou2. 1. College of Laboratory Medicine, Dalian Medical University, Dalian, 116044, Liaoning Province, China. jiali0386@sina.com. 2. College of Laboratory Medicine, Dalian Medical University, Dalian, 116044, Liaoning Province, China. 3. Department of Traumatology, Shanghai Ruijin Hospital, Jiaotong University, Shanghai, 200025, China. 4. College of Stomatology, Dalian Medical University, Dalian, 116044, Liaoning Province, China.
Abstract
BACKGROUND: Metastasis is a leading cause of cancer-related death including colorectal cancer (CRC). MicroRNAs are known to regulate cancer pathways and to be expressed aberrantly in cancer. Aberrant sialylation is closely associated with malignant phenotype of tumor cells, including invasiveness and metastasis. AIM: This study aimed to investigate the association of miR-182 and miR-135b with proliferation and invasion by targeting sialyltransferase ST6GALNAC2 in CRC cells and explore the potential molecular mechanism. METHODS: We measured the levels of miR-182, miR-135b, and ST6GALNAC2 in a series of CRC cell lines and tissues using real-time PCR. Bioinformatics analysis and luciferase reporter assay were performed to test the direct binding of miR-182 and miR-135b to the target gene ST6GALNAC2. We also analyzed the possible role of miR-182/-135b on colony formation, wound healing, invasion, and tube formation. RESULTS: The expression of miR-182 and miR-135b was higher in tumor tissues compared to adjacent noncancerous tissues of CRC patients, as well as up-regulated in SW620 cells than in SW480 cells with different metastatic potential. By applying bioinformatics analysis and luciferase reporter assay, we identified ST6GALNAC2 as the direct target of miR-182/-135b. Furthermore, miR-182/-135b inhibited significantly ST6GALNAC2 expression, and consistently, ST6GALNAC2 mediated migration, adhesion, invasion, proliferation, and tumor angiogenesis in CRC cell lines. Additionally, PI3K/AKT signaling pathway was regulated by miR-182/135b, which was partially blocked by altered level of ST6GALNAC2 in CRC. CONCLUSIONS: The miR-182/-135b/ST6GALNAC2/PI3K/AKT axis may serve as a predictive biomarker and a potential therapeutic target in CRC treatment.
BACKGROUND: Metastasis is a leading cause of cancer-related death including colorectal cancer (CRC). MicroRNAs are known to regulate cancer pathways and to be expressed aberrantly in cancer. Aberrant sialylation is closely associated with malignant phenotype of tumor cells, including invasiveness and metastasis. AIM: This study aimed to investigate the association of miR-182 and miR-135b with proliferation and invasion by targeting sialyltransferase ST6GALNAC2 in CRC cells and explore the potential molecular mechanism. METHODS: We measured the levels of miR-182, miR-135b, and ST6GALNAC2 in a series of CRC cell lines and tissues using real-time PCR. Bioinformatics analysis and luciferase reporter assay were performed to test the direct binding of miR-182 and miR-135b to the target gene ST6GALNAC2. We also analyzed the possible role of miR-182/-135b on colony formation, wound healing, invasion, and tube formation. RESULTS: The expression of miR-182 and miR-135b was higher in tumor tissues compared to adjacent noncancerous tissues of CRC patients, as well as up-regulated in SW620 cells than in SW480 cells with different metastatic potential. By applying bioinformatics analysis and luciferase reporter assay, we identified ST6GALNAC2 as the direct target of miR-182/-135b. Furthermore, miR-182/-135b inhibited significantly ST6GALNAC2 expression, and consistently, ST6GALNAC2 mediated migration, adhesion, invasion, proliferation, and tumor angiogenesis in CRC cell lines. Additionally, PI3K/AKT signaling pathway was regulated by miR-182/135b, which was partially blocked by altered level of ST6GALNAC2 in CRC. CONCLUSIONS: The miR-182/-135b/ST6GALNAC2/PI3K/AKT axis may serve as a predictive biomarker and a potential therapeutic target in CRC treatment.
Authors: Mohit Sachdeva; Jeffrey K Mito; Chang-Lung Lee; Minsi Zhang; Zhizhong Li; Rebecca D Dodd; David Cason; Lixia Luo; Yan Ma; David Van Mater; Rebecca Gladdy; Dina C Lev; Diana M Cardona; David G Kirsch Journal: J Clin Invest Date: 2014-09-02 Impact factor: 14.808
Authors: B Vanhaesebroeck; S J Leevers; K Ahmadi; J Timms; R Katso; P C Driscoll; R Woscholski; P J Parker; M D Waterfield Journal: Annu Rev Biochem Date: 2001 Impact factor: 23.643
Authors: Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein Journal: J Cell Physiol Date: 2013-08 Impact factor: 6.384
Authors: Petra Faltejskova; Ondrej Bocanek; Milana Sachlova; Marek Svoboda; Igor Kiss; Rostislav Vyzula; Ondrej Slaby Journal: Cancer Biomark Date: 2012 Impact factor: 4.388
Authors: Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón Journal: Cancer Treat Rev Date: 2004-04 Impact factor: 12.111
Authors: Nirupa Murugaesu; Marjan Iravani; Antoinette van Weverwijk; Aleksandar Ivetic; Damian A Johnson; Aristotelis Antonopoulos; Antony Fearns; Mariam Jamal-Hanjani; David Sims; Kerry Fenwick; Costas Mitsopoulos; Qiong Gao; Nick Orr; Marketa Zvelebil; Stuart M Haslam; Anne Dell; Helen Yarwood; Christopher J Lord; Alan Ashworth; Clare M Isacke Journal: Cancer Discov Date: 2014-02-11 Impact factor: 39.397
Authors: Matthew R Kudelka; Alison V Nairn; Mohammed Y Sardar; Xiaodong Sun; Elliot L Chaikof; Tongzhong Ju; Kelley W Moremen; Richard D Cummings Journal: Glycobiology Date: 2018-04-01 Impact factor: 4.313